1154 - Patient Monitor Module for non-invasive assessment of artificial stiffness and titration of anti-hypertensive medication in Chronic Kidney Disease
Assessment No | 1154 |
| Application Name | Non-invasive assessment of artificial stiffness by applantation tonometry for titration of anti-hypertensive medication in Chronic Kidney Disease (CKO). |
| Withdrawn by Applicant | |
| Description Of Medical Service | The measurement of the AiX for estimation of arterial stiffness and monitoring/titration of anti-hypertensive medication. |
| Description Of Medical Condition | CKD refers to all conditions of the kidney, lasting at least three months, where a person has had evidence of kidney damage and/or reduced kidney function, regardless of the specific diagnosis of disease or condition causing the disease (National Kidney Foundation of America 2002). Evidence of kidney damage manifests as either urinary protein (proteinuria) or albumin (a type of protein that is a more sensitive and specific marker of kidney disease, albuminuria), blood in the urine (haematuria) or scarring detected by imaging tests. |
| Pre Assessment Meeting |  |
| Stage 2 – Suitability for Assessment | 7 April 2011 |
| Lodgment of Proposed DAP | 20 April 2011 |
| Stage 3 - 1st PASC (Draft DAP considered) | |
| Stage 3 – Release for Public Comment (Consultation DAP) | |
| Stage 3 - 2nd PASC (Final DAP) | |
| Stage 4 - Submission of Collated Evidence | |
| Stage 5 - ESC evaluation | |
| Stage 6 - MSAC Appraisal | |
| Stage 6 - MSAC advice | |
| Stage 7 - Noting by Minister | |
| Stage 8 - Implementation | |
Page currency, Latest update: 09 April, 2013